5-ethynyl-1-ribofuranosylimidazole-4-carboxamide has been researched along with mycophenolic acid in 4 studies
| Studies (5-ethynyl-1-ribofuranosylimidazole-4-carboxamide) | Trials (5-ethynyl-1-ribofuranosylimidazole-4-carboxamide) | Recent Studies (post-2010) (5-ethynyl-1-ribofuranosylimidazole-4-carboxamide) | Studies (mycophenolic acid) | Trials (mycophenolic acid) | Recent Studies (post-2010) (mycophenolic acid) |
|---|---|---|---|---|---|
| 21 | 0 | 2 | 9,029 | 1,506 | 3,772 |
| Protein | Taxonomy | 5-ethynyl-1-ribofuranosylimidazole-4-carboxamide (IC50) | mycophenolic acid (IC50) |
|---|---|---|---|
| Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) | 0.1496 | |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | 0.014 | |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | 0.014 | |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | 0.014 | |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | 0.014 | |
| Inosine-5'-monophosphate dehydrogenase 1 | Homo sapiens (human) | 0.0772 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.011 | |
| Inosine-5'-monophosphate dehydrogenase | Cryptococcus neoformans var. neoformans JEC21 | 0.12 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balzarini, J; Bohman, C; De Clercq, E; Fridland, A; Herdewijn, P; Horská, K; Karlsson, A; Van Aerschot, A; Votruba, I; Wang, L | 1 |
| Balzarini, J; De Clercq, E; Leyssen, P; Neyts, J | 1 |
| Bailey, K; Barnard, DL; Carson, DA; Cottam, HB; Day, CW; Heiner, M; Hoopes, J; Lauridsen, L; Lee, J; Li, JK; Montgomery, R; Sidwell, RW; Winslow, S | 1 |
| Günther, S; Neyts, J; Ölschläger, S | 1 |
4 other study(ies) available for 5-ethynyl-1-ribofuranosylimidazole-4-carboxamide and mycophenolic acid
| Article | Year |
|---|---|
Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis.
Topics: Adenosine; Animals; Antineoplastic Agents; Cell Division; Deoxyguanine Nucleotides; Guanine; Guanosine; Guanosine Triphosphate; Humans; IMP Dehydrogenase; Leukemia L1210; Lymphocytes; Mice; Mycophenolic Acid; Purine Nucleotides; Ribavirin; Ribonucleosides; Ribonucleotides; Tumor Cells, Cultured | 1993 |
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Guanosine Triphosphate; IMP Dehydrogenase; Microbial Sensitivity Tests; Mycophenolic Acid; Parainfluenza Virus 3, Human; Ribavirin; Ribonucleosides; Vero Cells; Virus Replication; Yellow fever virus | 2005 |
Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.
Topics: Animals; Antiviral Agents; Caco-2 Cells; Cell Survival; Chlorocebus aethiops; Cytokines; Cytopathogenic Effect, Viral; Female; Humans; IMP Dehydrogenase; Lung; Mice; Mice, Inbred BALB C; Mycophenolic Acid; Oligonucleotide Array Sequence Analysis; Ribavirin; Ribonucleosides; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Specific Pathogen-Free Organisms; Vero Cells; Virus Replication | 2006 |
Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Ebolavirus; Guanosine; Guanosine Triphosphate; IMP Dehydrogenase; Lassa virus; Mycophenolic Acid; Ribavirin; Ribonucleosides; Vero Cells; Virus Replication | 2011 |